drugset
drugset / Trial / NCT05349474

Metformin Treatment in Progressive Multiple Sclerosis

NCT05349474 ↗

Phase 0 Completed 23 enrolled University of California, Los Angeles
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Timeline

Start
2022-04-26
Primary completion
2025-05-30
Completion
2025-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 2000 mg Oral

Indications

primary progressive multiple sclerosis secondary progressive multiple sclerosis